Drugs / Bapotulimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03666273 | Sep 2018 → Jun 2023 | head and neck squamous cell carcinoma | Bayer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bapotulimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03666273 ↗ |
| Known as | BAY1905254 | “Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab...” NCT03666273 ↗ |
| Route | Intravenous | “Intravenous administration of escalating doses of Bapotulimab” NCT03666273 ↗ |